Efficacy and safety of sunvozertinib in treatment naive NSCLC patients with EGFR exon20 insertion mutations

被引：0
|
作者：
Xu, Yan
Yang, James Chih-Hsin
Chiu, Chao-Hua
Hsu, Ping-Chih
Mitchell, Paul
Chang, Chia Lun
John, Tom
Bazhenova, Lyudmila
Kim, Tae Min
Yip, Ching Wan
Wang, Mengzhao
Janne, Pasi A.
Zhou, Caicun
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[4] Taipei Vet Gen Hosp, Taipei, Taiwan
[5] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Taoyuan, Taiwan
[6] Austin Hosp, Melbourne, Vic, Australia
[7] Wan Fang Hosp, Taipei, Taiwan
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[10] Seoul Natl Univ Hosp, Seoul, South Korea
[11] Dizal Pharmaceut, Shanghai, Peoples R China
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
[13] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations
    Bazhenova, L.
    Yang, J. Chih-Hsin
    Wang, M.
    Mitchell, P.
    Camidge, D. Ross
    Fang, J.
    Nian, W.
    Chiu, C. -H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Yang, T. -Y.
    Zhu, V. W.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Zheng, L.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E3 - E3
  • [2] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
    Yang, J. C. -H.
    Wang, M.
    Mitchell, P.
    Fang, J.
    Nian, W.
    Chiu, C-H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Camidge, R.
    Yang, T. -Y.
    Zhu, V.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Brungs, D.
    Bazhenova, L. B.
    Lee, C. K.
    Gao, B.
    Zheng, L.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S410 - S411
  • [3] Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
    Yang, J. C-H.
    Wang, M.
    Chiu, C-H.
    Hsu, P-C.
    Mitchell, P.
    Chang, C. L.
    Kim, T. M.
    John, T.
    Greillier, L.
    Bazhenova, L.
    Carcereny, E.
    Spira, A. I.
    Shim, B.
    Lee, K. H.
    Cobo Dols, M.
    Ghiringhelli, F.
    Yip, C. W.
    Xiong, J.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [4] Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results
    Wang, Mengzhao
    Fan, Yun
    Sun, Meili
    Wang, Yongsheng
    Zhao, Yanqiu
    Jin, Bo
    Hu, Ying
    Han, Zhigang
    Song, Xia
    Liu, Anwen
    Tang, Kejing
    Ding Cuimin
    Liang, Li
    Wu, Lin
    Gao, Junzhen
    Wang, Jianghong
    Cheng, Ying
    Zhou, Jianying
    He, Yong
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
    Janne, Pasi A.
    Wang, Mengzhao
    Camidge, D. Ross
    Mitchell, Paul
    Fang, Jian
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola Weijia
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Zheng, Li
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
    Zhou, Xiaoyue
    Dong, Huajie
    Li, Peng
    Wu, Changling
    Lu, Hongjun
    Xiao, Mingzhe
    Zhou, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Molecular characteristics of EGFR exon20 mutations in NSCLC patients.
    Ji, Yinghua
    Wang, Jin
    Meng, Xiangli
    Xie, Jinling
    Lu, Ping
    Li, Mengmeng
    Luo, Ningning
    Qi, Yingxue
    Zhu, Xiaofeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
    Yang, James Chih-Hsin
    Wang, Mengzhao
    Mitchell, Paul
    Fang, Jian
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Camidge, D. Ross
    Yang, Tsung-Ying
    Zhu, Viola Weijia
    Millward, Michael
    Fan, Yun
    Huang, Wen Tsung
    Cheng, Ying
    Jiang, Liyan
    Zheng, Li
    Ye, Xiuhui
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
    Wang, M.
    Fan, Y.
    Sun, M.
    Wang, Y.
    Zhao, Y.
    Jin, B.
    Hu, Y.
    Han, Z.
    Song, X.
    Liu, A.
    Tang, K.
    Ding, C.
    Liang, L.
    Wu, L.
    Gao, J.
    Wang, J.
    Cheng, Y.
    Zhou, J.
    He, Y.
    Dong, X.
    Yao, Y.
    Yu, Y.
    Wang, H.
    Sun, S.
    Huang, J.
    Fang, J.
    Li, W.
    Wang, L.
    Ren, X.
    Zhou, C.
    Hu, Y.
    Zhao, D.
    Yang, R.
    Xu, F.
    Huang, Y.
    Pan, Y.
    Cui, J.
    Xu, Y.
    Zhu, X.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S150 - S150
  • [10] A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
    Choi, D.
    Jung, H. A.
    Park, S.
    Sun, J-M.
    Ahn, J. S.
    Ahn, M-J.
    Lee, S-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1696
12345